Mesenchymal Stromal Cells’ Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?

Mesenchymal Stromal Cells’ Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?

Polyglutamine (polyQ) diseases are a group of inherited neurodegenerative disorders caused by the expansion of the cytosine-adenine-guanine (CAG) repeat. This mutation encodes extended glutamine (Q) tract in the disease protein, resulting in the alteration of its conformation/physiological role and...

Full description

Bibliographic Details
Main Authors: Inês Barros, Adriana Marcelo, Teresa P. Silva, João Barata, David Rufino-Ramos, Luís Pereira de Almeida, Catarina O. Miranda
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Cellular Neuroscience
Subjects:
mesenchymal stromal cells
polyglutamine disorders
neurodegenerative disorders
cell therapy
extracellular vesicles
secretome
Online Access:https://www.frontiersin.org/article/10.3389/fncel.2020.584277/full

Internet

https://www.frontiersin.org/article/10.3389/fncel.2020.584277/full

Similar Items